BioBiz Buzz

In 2024, despite a challenging global financial climate, Switzerland’s biotech sector showed remarkable resilience, maintaining steady revenues of CHF 7.2 billion while achieving a 22% increase in capital investment. In this episode of BioBiz Buzz, host Mike Ward interviews Michael Altorfer, CEO of the Swiss Biotech Association, to discuss the findings and implications of the Swiss Biotech Report...

This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide.  Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative drug candidate, LIB-01.  Unlike conventional therapies, LIB-01 introduces a novel mechanism of action and...

In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics.  Cereno’s lead candidates, CS1 and CS014, leverage epigenetic modulation through histone deacetylase inhibition (HDACi) to address the root causes of diseases like pulmona...

This episode of BioBiz Buzz features Dr. Monika Paule, CEO and co-founder of Caszyme, a pioneering Lithuanian biotech company at the forefront of CRISPR-Cas technology.  Your host Mike Ward explores how Caszyme is expanding the boundaries of gene editing through novel enzyme discovery, delivery optimization, and strategic collaborations, enabling breakthroughs in therapeutics, diagnostics, and sus...